Adia Med Partners with Live Oak Health (dba QCM Biologics) as Distributor and Sells 30% Stake in Adia Labs for $1.5 Million
The distribution partner must buy exclusively from Adia Labs for all products it distributes under the partnership.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adia Med (ADIA) sold a 30% interest in Adia Labs to Live Oak Health, doing business as QCM Biologics, for $1.5 million.
The consideration includes $1.0 million in cash and a $500,000 promissory note payable to Adia Labs. Adia Med retains 70% ownership. Live Oak Health also received a two-year option to acquire an additional 10% stake for $500,000.
The sale is paired with a distribution partnership under which QCM Biologics will sell Adia Labs products through its existing sales force and buy exclusively from Adia Labs for products distributed under the partnership. Adia Med said the arrangement is intended to add outside distribution coverage rather than build it internally. A transaction-related Form 8-K has been filed.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointStake sale brings $1.0 million in cash to Adia Labs. 9.6% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.QCM Biologics distribution partnership adds its existing sales force with exclusive sourcing from Adia Labs.
Negative
- Major point30% interest sold reduces Adia Med's ownership in Adia Labs to 70%.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Two-year option allows Live Oak Health to acquire another 10% stake for $500,000. 4.8% of market cap
- Minor point$500,000 of consideration is a promissory note payable to Adia Labs, rather than cash.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Winter Park, Florida--(Newsfile Corp. - October 6, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced that it has sold a
Link to Form 8-K here: Inline Viewer: ADIA MED, INC. 8-K 2026-09-30
The transaction includes
Under the related distribution arrangement, QCM Biologics becomes another distributor of Adia Labs products and will sell those products through its existing sales force. Because Live Oak Health is acquiring an ownership interest in Adia Labs, the arrangement provides that it will buy exclusively from Adia Labs for all products it distributes under the partnership. Adia Med said the deal is intended to add an outside distribution channel rather than require the Company to build that coverage internally.
"We wanted a distributor with money in the business, not just a purchase order," said Larry Powalisz, Chief Executive Officer of Adia Med. "QCM comes in as a part owner and as another distributor, and the cash goes to Adia Labs. The option is there if Live Oak Health wants a larger stake."
Adia Labs products, including AdiaVita, are not FDA-approved to diagnose, treat, cure, or prevent any disease.
The Company's Form 8-K related to the transaction is available at www.sec.gov.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-231-2843.
About Adia Med Inc.
Adia Med Inc. (OTCQB: ADIA), headquartered in Winter Park, Florida, is a regenerative medicine company built around active, IRB-approved stem cell therapy studies. Through its Adia Med clinics, the company delivers stem cell treatments alongside complementary services like platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT), supported by multiple Institutional Review Board (IRB)-approved clinical studies, The current studies are targeting autism spectrum disorder, chronic kidney disease, and lower back pain, with more planned for 2026. Its Adia Labs division manufactures regenerative products (AdiaVita, AdiaLink) that supply this clinical work.
Adia Labs generates revenue by manufacturing and selling regenerative products (AdiaVita and AdiaLink) to Adia Med clinics and external providers. Adia Med clinics generate revenue through patient treatments (stem cell therapies, PRP, TPE, and aHSCT). Additional revenue comes from the company's
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @adia_med
Instagram: @adia_med
Facebook: @adia_med
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/317634
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of Adia Med's Adia Labs stake sale to Live Oak Health?
Live Oak Health purchased a 30% interest in Adia Labs for $1.5 million, comprising $1.0 million in cash and a $500,000 promissory note payable to Adia Labs. Adia Med retains 70% ownership. Live Oak Health also received a two-year option to purchase an additional 10% stake for $500,000.
How does Adia Med's distribution partnership with QCM Biologics work?
QCM Biologics will distribute Adia Labs products through its existing sales force and buy exclusively from Adia Labs for products distributed under the partnership. Adia Med said the arrangement is intended to add an outside distribution channel rather than require it to build that coverage internally.